Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
31 janv. 2020 11h46 HE
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative...
Annovis Bio Announces Pricing of Initial Public Offering
28 janv. 2020 23h31 HE
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the...
Annovis Appoints Jeffrey McGroarty Chief Financial Officer
09 juil. 2019 08h45 HE
|
Annovis Bio, Inc.
BERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...
QR Pharma Adopts new Corporate Name: Annovis Bio
24 juin 2019 13h30 HE
|
Annovis Bio, Inc.
BERWYN, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- QR Pharma, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...